Status:
TERMINATED
Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
American Cancer Society, Inc.
Conditions:
Breast Cancer
Eligibility:
FEMALE
19+ years
Phase:
NA
Brief Summary
1. Evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy and compare results to co-temporal volume change on grayscale ultrasound and post-treatm...
Eligibility Criteria
Inclusion
- Adult patients (age 19 years or older).
- Patients with newly diagnosed and untreated stage II and III breast cancer scheduled to undergo neoadjuvant chemotherapy.
- Patients with signed informed consent.
Exclusion
- Any history of prior radiation or chemotherapy for breast cancer.
- Patients who only have non-measurable disease.
- Patients who are medically unstable.
- Patients with other primary cancers requiring systemic treatment.
- Patients with cardiac shunts.
- Patients with unstable cardiopulmonary conditions.
- Patients with known pulmonary hypertension.
- Patients with known hypersensitivity to any component of Definity (R) microbubble contrast.
- Patients who are pregnant, breast-feeding or are planning to become pregnant during the study duration.
Key Trial Info
Start Date :
June 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2016
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01817374
Start Date
June 1 2015
End Date
July 1 2016
Last Update
January 26 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294